Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports - Reuters
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQdHJVWklEdmVwSjU0V2NiVjQyRjFpQUIwTGk4SVBaLXczMlA5Zk1rbFR2aEVzVzZIUG5pVkJ0QnRZSFF5NXdWczNrZ2JWRWFYQmZ3Wl9VUWd2Y3J0WndoWHpNSGJ3ZlVXNmJrOWFFckRoaTJZdV9oa0lCRllySlZPczVfWnZsNUttSTRWdWt2cFF6bUFiQm9vbW1RNzNZWlpzN0ljRnZnb0ZDNHdSRG1TZlVVdmFnTkNFcUdmdVJfZm1NQ1ktSEJXcS0wakFBdWJWRWlIZllPUEotazlG?oc=5" target="_blank">Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
NEWSLETTER: Genetic discovery yields clues toward reversal of Alzheimer's brain damage - Reuters
NEWSLETTER: Genetic discovery yields clues toward reversal of Alzheimer's brain damage Reuters
September 25, 2026 at 11:15 AMUS FDA advisers endorse Grail cancer test's benefits in key vote - Reuters
US FDA advisers endorse Grail cancer test's benefits in key vote Reuters
September 23, 2026 at 11:03 PMMerck's drug for diabetes-related eye disease meets trial goal - Reuters
Merck's drug for diabetes-related eye disease meets trial goal Reuters
September 24, 2026 at 02:52 PMWegovy maker Novo shares slump as management grilled on pricing, M&A - Reuters
Wegovy maker Novo shares slump as management grilled on pricing, M&A Reuters
September 21, 2026 at 01:21 PMWegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs - reuters.com
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs reuters.com
September 21, 2026 at 05:02 AMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PM